The efficacy of a new class of drugs for Pneumocystis carinii pneumonitis was demonstrated. 566C80, a hydroxynaphthoquinone, administered orally in a dose of >100 mg/kg of body weight per day prophylactically prevented P. carinii pneumonitis in 90% or more of rats, while all untreated control animals developed pneumonitis. When 566C80 (100 mg/kg per day) was administered for 3 weeks after P. carinu pneumonitis was established, therapy was totally effective and all of the untreated controls had progressive P. carinii pneumonitis. A dose of 566C80 of between 25 and 50 mg/kg per day protected 50% of the rats from P. carinii pneumonitis, and a dose of between 50 and 100 mg/kg per day cured 50% of those treated for P. carinii pneumonitis. Both prophylaxis and treatment with 566C80 were at least as effective as with trimethoprimsulfamethoxazole. Animals maintained on immunosuppression after completion of treatment remained free of P. carinii, suggesting a killing effect. Clearance of P. carinii was associated with levels of 60 ,ug or more of 566C80 per ml of plasma. This hydroxynaphthoquinone offers promise as an anti-P. carinii drug.
Until recently, Pneumocystis carinii pneumonitis was regarded as a relatively rare parasitic infection seen occasionally in infants and in immunocompromised adults. It could be controlled readily either with pentamidine isethionate or with trimethoprim-sulfamethoxazole (TMP-SMZ), the latter being preferred because of its oral bioavailability and its low level of adverse reactions. With the advent of acquired immune deficiency syndrome in the 1980s, the magnitude of the P. carinii pneumonitis problem has increased enormously. First, about 70% of acquired immune deficiency syndrome patients develop P. carinii pneumonitis, which is fatal if untreated. Second, for reasons that are still not clear, the frequency of serious adverse reactions with TMP-SMZ has increased to around 60% in patients with acquired immune deficiency syndrome, similar to that seen with pentamidine. Clearly, there is an urgent need for new drugs which are both highly efficacious and free from serious adverse reactions for the prophylaxis and therapy of P. carinii pneumonitis. We report here the efficacy of a new compound in the murine model of P. carinii pneumonitis which comes from a class of drugs strikingly different from those of other anti-P. carinii agents. The compound 2-[trans-4 -(4-chlorophenyl)cyclohexyl] -3 -hydroxy -1,4 -naphthoquinone (566C80 [Weilcome Research Laboratories, Beckenham, United Kingdom]), already in clinical development as an antimalarial agent, is effective by the oral route in both the prevention and treatment of P. carinii pneumonitis in the rat without obvious toxicity.
In 1946, it was noted that certain 2-hydroxy-3-alkylnaphthoquinones inhibited the respiratory processes of Plasmodium species (13) . Subsequently, these findings were substantiated by Fieser and his collaborators (3), though no drug suitable for human use was discovered. A variety of naphthoquinones were also found to have activity against other protozoa, including trypanosomes (1, 2, 10, 12) , Theileria parva (6, 11) , Toxoplasma spp. (6) , and certain Eimeria and Plasmodium species (6) . Hydroxynaphthoquinones * Corresponding author. block protozoal respiratory chain electron transport at complex III, probably by functioning as analogs of ubiquinone (4) .
There are no well-developed in vitro culture systems to measure the intrinsic susceptibility of P. carinii to drugs. The corticosteroid-treated rat model has been found to be remarkably similar to the human infection. This animal system is based on the premise that P. carinii pneumonitis can be provoked in over 90% of latently infected rats given dexamethasone and tetracycline for 4 to 6 weeks. Drugs found to be effective against P. carinii pneumonitis in these animals (9) have been shown subsequently to be equally effective in humans (8) .
The The animals were caged in groups of five and were fed standard rations. All rats received dexamethasone and tetracycline in drinking water continuously throughout the experiments. The rats used for study of the prophylactic effects of the drug were sacrificed in a carbon dioxide chamber after 6 weeks of study, and those studied for the therapeutic effects were sacrificed after 8 to 8.5 weeks of immunosuppression, although some animals died earlier. At autopsy, the lower lobe of the right lung was removed and bisected. One portion was placed in Formalin and processed for sections with Grocott-Gomori methenamine silver nitrate stain. The other portion of lung was imprinted from its cut surface onto microscope slides and stained separately with toluidine blue 0 or cresyl echt violet. The histological sections were coded and read by W. A second prophylactic study confirmed the activity of 566C80 at 100 mg/kg per day p.o. by gavage and in addition showed a dose-related effect in which smaller doses were less effective (50 mg/kg) or essentially ineffective (25 or 10 mg/kg). When the drug was administered in the rations rather than by gavage, infection was totally prevented in rats given either 200 or 100 mg/kg per day (Table 1) .
Animals were allowed to develop pneumonitis, and 566C80 was then administered to determine its therapeutic effect. A Beckenham study in which rats were treated with 566C80 at 100 mg/kg per day p.o. by gavage beginning after 6 weeks of immunosuppression, when P. carinii pneumonitis was in an advanced stage, yielded an 80% cure rate (Table  2) . Even better results were seen in the Memphis study, in which treatment was begun earlier, after 4 weeks of immunosuppression. All animals that received doses of 100 mg/kg per day were cured, as determined by histological examination, compared with an 80% cure rate with co-trimoxazole (TMP-SMZ) ( Table 2 ). Lower doses of the drug (50 and 25 mg/kg per day) were less effective.
To gain some insight into the killing and static effects of 566C80, immunosuppressed rats were treated in Memphis for 3 weeks with the equivalent of 100 mg/kg per day p.o. of drug in the diet beginning at the time dexamethasone administration was started. Animals were then continued on dexamethasone for a further 4 weeks after the last dose of 566C80 before sacrifice. Of the 10 animals managed in this manner, none had histologically discernible P. carinii infection, suggesting that, in contrast to pentamidine and cotrimoxazole (7), 566C80 has a killing effect on P. carinii.
The concentrations in plasma obtained 2 to 3.5 h and 1 week after the last gavage dose of 566C80 of the Memphis experiments shown in Table 1 and measured as coded samples in Beckenham are shown in Table 3 . Even though the parasites are sequestered in the lung, there is a correlation between concentration in plasma and level of infection (Fig. 1) .
DISCUSSION
The results show that a dose of 566C80 of between 25 and 50 mg/kg per day p.o. will protect 50% of rats from P. carinii pneumonitis and that a dose of between 50 and 100 mg/kg per day p.o. will cure 50% of those already infected. The dose of 100 mg/kg per day is totally effective in the treatment and prevention of the pneumonitis. These doses are markedly higher (>100 times) than those required to protect mice from rodent-infecting strains of malaria (5). However, no gross evidence of toxicity, such as early deaths, excessive weight loss, bleeding, diarrhea, or neurological deficits, was observed during our experiments. The preclinical toxicological studies carried out with the compound at Beckenham before human volunteer studies suggest that as an antimalarial agent, 566C80 has a very large therapeutic window. Furthermore, we have preliminary evidence to suggest that as with other protozoa, this compound exerts its antimicrobial effects via a blockade of electron transport. Its mode of action is thus quite distinct from those of the antifols (TMP, pyrimethamine, trimetrexate, piritrexim, SMZ, and dapsone), which together with pentamidine (whose mode of action is unknown) dominate not only those therapies already in clinical use but also those in development. There is a strong case for evaluating 566C80 in humans with P. carinii pneumonitis as soon as possible, especially in patients with acquired immune deficiency syndrome. We do not know at this stage whether the high 566C80 concentration in plasma that is likely to be required will be attainable and safe.
